Chile Pharmaceuticals and Healthcare Report Q2 2009

Publication Date	April 2009
Publisher	Business Monitor
Product Type	Report
Pages	77
ISBN Number	not applicable
Product Code	BMI03709

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$416 | €280

FAX Order above formats by FAX

Summary

Chile remains seventh overall in BMI's Q209 Business Environment Rankings for the 10 markets of the Americas. In the next five years, we expect that the country's pharmaceutical market will experience a compound annual growth rate (CAGR) of 7.38% in US dollar terms (or 4.81% in local currency terms, as the peso appreciates against the US dollar), reaching CLP802.81bn (US$1.73bn) at consumer prices in 2013. The main drivers of this trend will be economic growth (despite an expected blip of a slowdown in 2009), higher government spending, expansion of universal insurance and epidemiological concerns, as well as the expected introduction of tougher bioequivalence standards.

On the negative side, a key drawback to investing in the market comes from the government's minimal provision of or reimbursement for medicines, despite the expansion of government spending in recent years, particularly under the flagship Universal Access and Explicit Guarantees (AUGE) healthcare plan.

Similarly, future value growth will depend on the speed at which Chile aligns its intellectual property (IP) regulations with its international obligations. In this field, much depends on the government's success in balancing its healthcare reforms and the need to restrain cost growth with the desire to placate its international trading partners. Additionally, private sector retail drug prices remain low, primarily owing to intense retail sector competition, although formal pricing restrictions are relatively limited.

In the meantime, individuals in Latin America continue to succumb to generally preventable diseases such as gastric and cervical cancers. For example, BMI's Burden of Disease Database (BoDD) reveals that, in 2008, Chile lost 147,495 disability-adjusted life years (DALYs) to cancer. The growing cancer burden has recently led to launch of a new Office of Latin American Cancer Program Development (OLACPD) by the National Cancer Institute (NIC), the National Institutes of Health (NIH). The programme, which will initially focus on Mexico, Brazil, Chile, Argentina and Uruguay, aims to gain a better understanding of the status of the cancer burden, research and treatment infrastructures in those countries.

On an economic front, a stable political outlook and sound economic fundamentals position Chile for steady economic progress, and underpin our view that Chile's economy will head towards developed state status by 2018. While obstacles such as high reliance on copper exports and oil imports continue to limit the scope for economic progress, we see encouraging developments in both areas over the next ten years.

However, an economic recovery among Latin American economies will be vital for Chile, as regional trade will provide an important platform for growth in the next decade.

Content

Executive Summary
Chile Pharmaceuticals And Healthcare Industry SWOT
Chile Political SWOT
Chile Economic SWOT
Chile Business Environment SWOT
Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Chile - Market Summary
Regulatory Regime
Recent Regulatory Developments
Intellectual Property
IP Deficiencies
Recent IP Developments
Trade Agreements
Pricing Regime
Reimbursement Regime
Industry Developments
Epidemiology
DALYs Lost To All Diseases And Injuries Per 100,00 Population In Select South American Countries
Healthcare Sector
Healthcare Insurance
Pharmaceutical Sector
Domestic Industry
Foreign Industry
Recent Pharmaceutical Industry Developments
OTC Medicines
Pharmaceutical Retail Sector
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Prescription Market Forecast
Patented Market Forecast
Generics Market Forecast
OTC Market Forecast
Pharmaceutical Trade Forecast
Medical Devices Forecasts
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Monitor
Leading Multinationals
Pfizer
Novartis
GlaxoSmithKline (GSK)
Sanofi-Aventis
Merck & Co
Indigenous Companies
Laboratorios Chile (LabChile)
Laboratorios Andrmaco
Laboratorios Maver
Country Snapshot: Chile Demographic Data
Section 1: Population
Section 2: Education And Healthcare
Section 3: Labour Market And Spending Power
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
Sources
List of Tables
- Table: Americas Pharmaceutical Business Environment Ratings for Q209
- Table: Latin American Regulations On Bioequivalence And GMP
- Table: Chile - Drug Market Expenditure Indicators, Historical Data and Forecasts
- Table: Chile - Health Expenditure Indicators, Historical Data and Forecasts
- Table: Chile - Economic Activity
- Table: Chile - Prescription Market Indicators, Historical Data and Forecasts (CLPmn unless otherwise stated)
- Table: Chile - Patented Drug Market Indicators, Historical Data and Forecasts ...................................................Error! Bookmark not defined.
- Table: Chile - Generics Drug Market Indicators, Historical Data and Forecasts...................................................Error! Bookmark not defined.
- Table: Chile - OTC Market Indicators, Historical Data and Forecasts (CLPmn unless otherwise stated)
- Table: Chile - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn)
- Table: Chile - Medical Device Indicators, Historical Data And Forecasts (US$mn unless otherwise stated)
- Table: Chile - Other Healthcare Indicators, Historical Data and Forecasts
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

Delivery Details

PDF:Immediate delivery

Ask a question about this product

Need help finding the right product?

Product features / use

Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted